Humulin N

Humulin N is a recombinant DNA insulin human product supplied as a 100 IU/mL injectable suspension for subcutaneous administration. It is a prescription‑only antidiabetic agent marketed in the European Union and belongs to the insulin drug class, used to replace or supplement endogenous insulin in diabetes management.

Humulin N is indicated for the long‑acting control of blood glucose in patients with diabetes. It is commonly employed in the following clinical situations:

- Basal insulin therapy for type 1 diabetes mellitus. - Basal insulin therapy for type 2 diabetes mellitus. - Combination with rapid‑acting insulin analogues for intensive insulin regimens. - Use in adults, adolescents, and children when a stable, prolonged insulin effect is required. - Adjunct to diet and exercise for overall glycaemic management.

Adverse reactions to Humulin N vary in frequency and severity.

Common: - Injection site redness, swelling, or bruising. - Low blood glucose (hypoglycaemia) episodes. - Weight gain. - Lipodystrophy at injection sites.

Serious: - Severe hypoglycaemia with neuroglycopenic symptoms. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Persistent hypoglycaemia unresponsive to carbohydrate intake. - Edema or heart failure exacerbation in susceptible patients.

When prescribing or using Humulin N, consider the following precautions:

- Assess renal and hepatic function, as impairment may alter insulin requirements. - Monitor for signs of hypoglycaemia, especially in patients with irregular meals or increased physical activity. - Use caution in pregnant or breastfeeding individuals; safety data are limited. - Adjust doses when initiating or discontinuing concomitant medications that affect glucose metabolism. - Educate patients on proper injection technique to reduce lipodystrophy risk. - Review cardiovascular status, as fluid retention may worsen heart failure.

Humulin N may interact with several drug classes.

Avoid: - Concurrent use of other insulin products without dose adjustment, which can precipitate severe hypoglycaemia. - Beta‑blockers that mask hypoglycaemia symptoms.

Use with caution: - Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides) that increase insulin secretion. - Corticosteroids, which raise blood glucose and may require higher insulin doses. - Diuretics, particularly thiazides, that can impair glucose tolerance. - ACE inhibitors or ARBs, which may potentiate insulin’s glucose‑lowering effect. - Alcohol, which can cause unpredictable glucose fluctuations.